We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Studie nových antikoagulancií -- dílčí výsledky.
- Authors
ZATLOUKALOVÁ, A.; JANOUTOVÁ, J.; HOMZA, M.; FEDIČOVÁ, M.; JANOUT, V.
- Abstract
Until recently, warfarin was the only anticoagulant used in medical care. Because of its numerous side effects, especially various types of bleeding, new oral anticoagulants have been developed with the same or better safety. To date, several preparations have been developed, direct thrombin inhibitors (so-called gatrans) and direct inhibitors of haemocoagulation factor Xa (so-called xabans). To prevent CMP and other systemic of embolization events in patients with atrial fibrillation, the following substances (in the order in which they are listed) have been registered as a result of large clinical trials: dabigatran, rivaroxaban and apixaban. They have the same or better safety profile, but they need to be monitored for epidemiological reasons over the long term. There is also a need for more information on managing patients with bleeding because, with the exception of dabigatran, a specific antidote for other NOACs (NOvel Oral AntiCoagulantS) is not approved. The study included patients from cardiology ambulance taking new anticoagulants. Their basic characteristics were identified and, in particular, the adverse effects were observed. It was further investigated whether the occurrence of adverse events was related, for example, to the age of the patient or to the BMI group. The group contained 150 patients, which were divided into three groups according to the above mentioned anticoagulants. The primary objective of the study was to compare adverse events between all three of these anticoagulants. Statistical significance was set at 5%. The most bleeding effects had Xarelto, followed by Pradaxa. Eliquis was completely bleeding-free. Other side effects that included gastro-intestinal problems, allergies, and more were most common with Eliquis. There was no statistically significant difference between the BMI groups, among the sexes and between age groups in the occurrence of adverse events for each anticoagulants and theme. This issue needs to be further addressed. More data is required for more valid results, so data collection will continue until the end of this year and the data will be analyzed again and evaluated. Practice recommendations will also be given after this step.
- Publication
General Practitioner / Praktický Lékař, 2017, Vol 97, Issue 6, p259
- ISSN
0032-6739
- Publication type
Article